Merck & Co., Inc., known as MSD outside of the United States and Canada, and Eisai Co., Ltd. announced that their Phase 3 LITESPARK-012 trial did not achieve its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for the treatment of advanced clear cell renal cell carcinoma (RCC). The trial evaluated combination therapies involving KEYTRUDA, LENVIMA, and WELIREG against the established treatment of KEYTRUDA plus LENVIMA.
The study explored whether combining therapies with known efficacy could improve outcomes compared to the current standard of KEYTRUDA-based regimens. Despite not meeting the desired results, the trial provided valuable insights into advanced RCC, according to Dr. M. Catherine Pietanza, Vice President of Global Clinical Development at MSD Research Laboratories.
Dr. Corina Dutcus, Senior Vice President at Eisai Inc., emphasized that the findings underscore the importance of KEYTRUDA plus LENVIMA in RCC's first-line treatment. The trial's results will contribute to shaping future treatment paradigms for advanced RCC.
The LITESPARK-012 trial enrolled 1,688 patients and compared the efficacy of two combination regimens: the triplet therapy of KEYTRUDA, LENVIMA, and WELIREG, and a coformulation of KEYTRUDA and quavonlimab with LENVIMA, against the standard treatment of KEYTRUDA plus LENVIMA.
Despite the trial's setback, ongoing research efforts continue, including other studies within the LITESPARK clinical program. The U.S. Food and Drug Administration has accepted two supplemental New Drug Applications based on another trial, LITESPARK-011, evaluating WELIREG in combination with LENVIMA for previously treated advanced RCC patients, with a decision expected by October 2026.
RCC is the most common form of kidney cancer, with clear cell RCC accounting for about 70% of cases. The disease is more prevalent in men and often diagnosed at an advanced stage, making effective first-line treatments crucial for patient outcomes.
Comments are closed.